Skip to main content

Table 1 Demographics and baseline characteristics of participants in both groups

From: SMS reminders to improve adherence and cure of tuberculosis patients in Cameroon (TB-SMS Cameroon): a randomised controlled trial

Variables Intervention group
(DOT + SMS) n = 137
Control group
(DOT) n = 142
Gender: n (%)
 Male 86 (62.8) 79 (55.6)
 Female 51 (37.2) 63 (44.4)
Age (years): n (%)
 18–25 22 (16.1) 34 (23.9)
 26–40 84 (61.3) 79 (55,7)
 41–55 26 (18.9) 20 (14,1)
 56–80 5 (3.7) 9 (6,3)
Level of Education: n (%)
 None 7 (5.2) 4 (2.9)
 Nusery/primary 38 (27.9) 34 (23.9)
 Secondary 69 (50.1) 74 (52.1
 Tertiary 23 (16.8) 30 (21.1)
Marital Status: n (%)
 Single 84 (61.3) 93 (65.5)
 Married 40 (29.1) 37 (26.0)
 Cohabitation 11 (8.0) 7 (5.0)
 Widower 1 (0.8) 5 (3.5)
 Divorced 1 (0.8) 0 (0.0)
Social Category: n (%)
 Student 21 (15.3) 25 (17.6)
 Working in public sector 7 (5.1) 14 (9.8)
 Working in formal private sector 20 (14.6) 15 (10.6)
 Working in informal private sector 41 (30.0) 37 (26.0)
 No work 48 (35.0) 51 (36.0)
Monthly Income (XAF): n (%)
  < 50,000 40 (29.2) 31 (21.8)
 50,000–149,000 20 (14.6) 25 (17.6)
  > 149,000 5 (3.7) 3 (2.1)
 Not reported (missing) 72 (52.5) 83 (58.5)
HIV Status: n (%)
 Negative 85 (62.0) 98 (69.0)
 Positive 27 (19.7) 12 (8.5)
 Unknown 25 (18.3) 32 (22.5)
Patient on ART (yes): n (%) 10 (7.3) 7 (4.9)
Microscopy (positive): n (%) 137 (100) 142 (100)
Treatment plan (2RHEZ/4RH): n (%) 137 (100) 142 (100)
Duration of treatment (months):
Mean (SD) / Median (Q1-Q3)
6.6 (1.2) /
6.2 (6.0–6.7)
6.5 (1.3) /
6.1 (6.0–6.6)
  1. DOT directly observed treatment, SMS short message service, 1 US Dollar 599 XAF (F CFA, currency used in Cameroon), HIV human immunodeficiency virus, ART anti-retroviral therapy, 2RHEZ/4RH 2 months of rifampicin, isoniazid, ethambutol, pyrazinamide and 4 months of rifampicin and isoniazid, SD standard deviation, Q1 first quartile, Q3 third quartile